DGCI's Subject Expert Committee recommends waiving off 'clinical trial mode' from Covaxin

After more than two hours of deliberation on Wednesday, the SEC in its recommendation to the drug regulator asked for the removal of clinical trial mode from Covaxin on the basis of the efficacy data that was presented by the company before the SEC. Hyderabad-based Bharat Biotech had approached the drug regulator for the removal of Covaxin vaccine from “clinical trial mode” and review the interim analysis of its phase-3 trials.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news